News | October 30, 2024
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Stable profits, low leverage to keep credit profiles comfortable
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Subscribe To Our Newsletter & Stay Updated
